Letrozole is used in IVF primarily to stimulate the ovaries to produce eggs, often as part of a combination protocol with injectable hormones. It works by temporarily lowering estrogen levels, which tricks the brain into ramping up its own fertility signals. Beyond egg retrieval cycles, letrozole also plays a role in preparing the uterus for frozen embryo transfers and is a go-to medication for women with polycystic ovary syndrome (PCOS) who need help ovulating before or during fertility treatment.
How Letrozole Works
Letrozole belongs to a class of drugs called aromatase inhibitors. It blocks the enzyme responsible for converting other hormones into estrogen, which temporarily drops your estrogen levels. Your brain interprets this dip as a signal that more follicle development is needed, so it increases production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). That surge of FSH is what drives the ovaries to develop follicles and mature eggs.
There’s also evidence of a secondary effect happening directly in the ovaries. By temporarily increasing local androgen levels around the follicles, letrozole may make them more sensitive to FSH. Think of it as a two-pronged approach: more FSH coming from the brain, and ovaries that respond more readily to it.
One important distinction from clomiphene (Clomid), the other common oral fertility drug: letrozole doesn’t block estrogen receptors. It simply reduces how much estrogen your body makes. This matters because clomiphene’s anti-estrogen effects can thin the uterine lining, which is a problem when you need a thick, receptive lining for an embryo to implant. Letrozole also has a much shorter half-life, meaning it clears your system faster and doesn’t linger in your body the way clomiphene can.
Ovarian Stimulation During IVF Cycles
In a standard IVF cycle, letrozole is often paired with injectable gonadotropins rather than used alone. Adding letrozole to the stimulation protocol serves several purposes depending on the patient’s situation.
For women with estrogen-sensitive conditions like breast cancer, letrozole is essential. It keeps estrogen levels lower during ovarian stimulation, which is critical when high estrogen exposure could fuel tumor growth. This combination has become widely accepted as the standard approach for fertility preservation in these patients.
For women with poor ovarian response (meaning the ovaries don’t produce many eggs with standard protocols), combining letrozole with a gonadotropin antagonist protocol has been proposed to improve follicular response and oocyte quality. The idea is that letrozole’s ability to boost the body’s own FSH production complements the injectable hormones, potentially coaxing more follicles to develop.
There’s also a practical benefit for any woman undergoing IVF: lower estrogen levels during stimulation reduce the risk of ovarian hyperstimulation syndrome (OHSS), a painful and sometimes dangerous complication where the ovaries over-respond to fertility drugs. Recent research also suggests that letrozole co-treatment extending into the luteal phase (the days after egg retrieval) can counteract the negative effects of high cumulative estrogen on both egg quality and the receptivity of the uterine lining. This can create a more natural hormonal environment if an embryo transfer is planned in the same cycle.
Preparing for Frozen Embryo Transfers
Letrozole has a distinct role in frozen embryo transfer (FET) cycles, which is separate from its use during egg retrieval. When you’re transferring a previously frozen embryo, your doctor needs your uterine lining to be thick and receptive, timed precisely with ovulation or a hormonal schedule. There are three common ways to prepare for this: a natural cycle relying on your own ovulation, a programmed cycle using estrogen and progesterone medications, or a letrozole-induced cycle.
In a letrozole FET cycle, the medication triggers ovulation so that the transfer can be timed accordingly. The embryo transfer typically happens six days after the LH surge (the hormonal signal that confirms ovulation is imminent). Progesterone supplementation begins two days after the surge to support the lining, and it’s usually stopped around 7 to 8 weeks of pregnancy, which is earlier than the 10 to 12 weeks required in fully programmed cycles.
The outcomes are encouraging. A study published in Fertility and Sterility found that ongoing pregnancy and live birth rates were about 11% higher with letrozole FET cycles compared to programmed cycles. Letrozole cycles performed comparably to natural cycles, making them a strong alternative for women who don’t ovulate on their own and would otherwise need a fully medicated protocol.
First-Line Treatment for PCOS
For women with PCOS, letrozole has become the preferred first-line medication for inducing ovulation, whether the goal is timed intercourse, intrauterine insemination, or preparation for IVF. PCOS is the most common cause of anovulation (not releasing eggs), and getting ovulation to happen reliably is often the first step in any fertility plan.
A large NIH-supported trial involving 750 women with PCOS compared letrozole to clomiphene over up to five treatment cycles. The results were clear: women taking letrozole had a cumulative live birth rate of 28%, compared to 19% for clomiphene. Ovulation rates were also significantly higher with letrozole, at 62% versus 48%. Pregnancy loss rates were similar between the two groups (around 30%), and twin pregnancy rates didn’t differ significantly (3% with letrozole versus 7% with clomiphene).
Clomiphene resistance is a real problem in PCOS. Roughly 20% to 25% of women with the condition don’t respond to it at all. Even among those who do ovulate on clomiphene, some fail to conceive because the drug thins the uterine lining, making implantation difficult. Letrozole avoids this issue. Clinical data consistently shows that letrozole produces a thicker endometrium than clomiphene, with measurements typically around 8 to 10 mm, compared to the sometimes problematically thin linings seen with clomiphene. An endometrial thickness below 7 mm with letrozole is rare.
What a Typical Letrozole Cycle Looks Like
The standard dose is 2.5 mg taken by mouth once daily for five days, starting on day two of your menstrual cycle and continuing through day six. If blood work around day 21 shows that progesterone levels are below the target threshold (indicating you didn’t ovulate strongly enough), the dose may be increased in the following cycle. Doses can go up to 5 mg or even 7.5 mg daily depending on your response.
When letrozole is used alongside injectable hormones in an IVF stimulation protocol, the timing and dosing may differ from a simple ovulation induction cycle. Your clinic will monitor you with blood tests and ultrasounds to track follicle growth and adjust the plan accordingly.
Common Side Effects
Because letrozole temporarily lowers estrogen, the most common side effects resemble mild menopausal symptoms. Hot flashes are the most frequently reported. Some women also experience fatigue, dizziness, or headaches during the five days they’re taking it. These effects are typically mild and resolve quickly once the medication is stopped, largely because of letrozole’s short half-life.
Less common side effects include breast tenderness, mood changes, and joint discomfort. The short course used in fertility treatment (five days per cycle) produces far fewer side effects than the long-term daily use seen in breast cancer treatment, where the drug is taken for years. Most women tolerate the fertility dosing well, and serious side effects during short-course use are rare.